Home >> Tag Archives: Agilent Technologies—

Tag Archives: Agilent Technologies—

Agilent companion Dx gets expanded approval

August 2018—Agilent Technologies announced that the FDA has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use. PD-L1 IHC 22C3 pharmDx is a laboratory test doctors can use to identify the protein programmed cell death ligand 1 in tumor tissue obtained from patients with lung and gastric cancer.

Read More »

FDA expands use of Agilent CDx for gastric cancer

Oct. 20, 2017—Agilent Technologies announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by the FDA for use as an aid in identifying gastric or gastroesophageal junction adenocarcinoma patients for treatment with Keytruda (pembrolizumab), an anti-PD-1 therapy manufactured by Merck. The FDA also announced that Keytruda is approved for the treatment of patients with recurrent locally ...

Read More »

FDA expands use of Agilent CDx

Sept. 28, 2017—Agilent Technologies announced that the FDA has approved the cancer diagnostic PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The test had previously been approved for melanoma and nonsquamous, non-small cell lung cancer. PD-L1 IHC 28-8 pharmDx, developed in collaboration with Bristol-Myers Squibb, enables physicians ...

Read More »

Newsbytes, 7/15

July 2015—Why Sonora Quest gave itself high marks for LIS conversion; Pathologists share homegrown software for infant autopsies; CMS promotes innovation by offering data to private sector; Agilent purchases Cartagenia; Database provides information from next-gen sequencing

Read More »

Agilent buys next-gen software firm Cartagenia

May 18, 2015—Agilent Technologies recently announced a definitive agreement to acquire Cartagenia, a provider of software and services for clinical genetics and molecular pathology labs. Cartagenia, which has offices in Leuven, Belgium, and Boston, provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays. Geared to routine clinical labs, Cartagenia’s solutions are FDA-registered ...

Read More »

SureFISH probes, 3/14

March 2014—Agilent Technologies introduced SureFISH ALK, ROS1, and RET break-apart translocation probes, expanding its offering of oligonucleotide-based fluorescent in situ hybridization products. The probes are repeat-free, able to target specific sequences of interest, and use high-fidelity oligos designed in silico.

Read More »